Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical is currently conducting XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in early 2019.
ANT01, a Phase IIa proprietary small molecule in the Prevention of Alzheimer Disease in well defined patients, is oriented to prevent in the US only at least 100.000 new AD cases per year by treatment of 1M patients life time. After 5 years of planned launch in 2030 and with a peak sales of 10B, this will save US healthcare costs by at least 50B giving ANT01 a very attractive value proposition.
Up till date, via clinical case studies, we were able to demonstrate that short term intervention with ANT01 led to a clinical relevant diminishment of the identified clinical risk factors for the development of Alzheimer Disease.
Objectives of ANT’ 2019-2022 Business Plan are: Further Development & Validation of ANT’s Marker in Prevention of Alzheimer Disease (Milestone 1) Proof of Concept Study in Prevention of Alzheimer Disease based on ANT’ Marker (Milestone 2) Phase IIA Study with ANT’ Marker on ANT01 in Prevention of Alzheimer Disease (Milestone 3)
The Proceeds required for these milestones in a Series A investment round will add up to 50 M USD i.e.: MS1: 5 M USD (tranche 1) MS2: 15 M USD (tranche 2) MS3: 30 M USD (tranche 3) http://www.aneurotech.com
AZTherapies is an advanced clinical stage pharmaceutical company based in Boston, MA. AZTherapies is using innovative approaches in the discovery, development and commercialization of novel Alzheimer’s Disease and ischemic stroke treatments which could fundamentally improve patient treatment, quality of life and disease management.
Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's disease.
I invite you to spend a few minutes exploring our website and getting to know us. Our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options.
We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is fed by highly productive drug discovery platforms that includes MultiCore®, our proprietary chemistry capability.
At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. This means we can focus our strengths in innovative drug discovery to extract as many "shots on goal" from our diverse pipeline in the quest to create the world's new blockbuster drugs.
We have a passion for what we do and we work with the best in the world to deliver meaningful outcomes from our discoveries. We look forward to you accompanying us on this extremely valuable journey.
Brainstorm Cell Therapeutics, Inc. - [NASDAQ:BCLI]
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. We believe that we are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults
Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
MISSION At CV Sciences, our mission to improve well‐being underscores our values, operations, and products.
OVERVIEW CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state‐of‐the art production facilities.
PHARMACEUTICALS CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions.
CONSUMER PRODUCTS CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider’s offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician’s recommendations.
Emerald Health Sciences is a diversified cannabis company positioned to take advantage of the significant projected growth in different segments of the cannabis industry.The target segments are Pharmaceuticals, Botanicals (Medical and Recreational), and Bioceuticals. Each investment leverages the scientific rigor, federal regulatory compliance, and life-science expertise of Emerald Health Sciences’ leadership.
Engage Therapeutics is focused on bringing patients with epilepsy suffering from uncontrolled seizures what could be the first rescue treatment with the potential to stop their seizures.
Epilepsy affects at least three million people in the United States. One in three of those people have what is considered refractory epilepsy with uncontrolled seizures, as one or more anti-epileptic drugs has not worked for them. Approximately twenty percent or 200,000 of these patients have a predictive pattern of seizures, and Engage Therapeutics is working to bring these patients Staccato alprazolam, which is designed to stop a seizure in patients who have a predictable seizure pattern.
In 2017, the company entered into an exclusive license and supply agreement with Alexza Pharmaceuticals to advance Staccato alprazolam into phase 2b development as a treatment to stop seizure activity. Founded by a leadership team with deep personal and professional experience in epilepsy, Engage Therapeutics is headquartered in Summit, NJ.
Kalgene is developing a novel fusion protein therapeutic for slowing the progression of Alzheimer’s disease, with technology licensed from the National Research Council of Canada. The therapeutic targets the toxic soluble amyloid and the clinical program will focus on patients with early clinical signs of cognitive decline, before progressive neural damage causes dementia.
Today we’ve completed pre-clinical proof of concept work in partnership with the NRC and McGill University. These studies have shown that the development candidate passes through the blood brain barrier and rapidly induces CSF-amyloid-beta clearance. PET studies in rat models of the disease showed dramatic plaque removal. In an aged rat disease model, neuronal connectivity using diffusion weighted MRI was vastly improved, hippocampal volume was increased and no increase in micro-hemorrhages was observed.
M3 Biotechnology is a clinical-stage company with a novel platform of disease-modifying therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3 Biotechnology is conducting Phase I clinical trials of its lead therapy for Alzheimer’s, which is designed to slow or stop disease progression as indicated by preclinical studies.
Metys Pharmaceuticals is developing dimiracetam for the prevention of che- motherapy-induced painful peripheral neuropathy. In the US alone, in a single year, more than 400’000 patients suffer from the neuropathy caused by their life-saving cancer treatment. No drug has been approved to prevent or treat this condition. Dimiracetam is an orally active, small molecule with more than 200 patients’ safety and tolerability data; dimiracetam is highly effective in prevent- ing and treating chemotherapy-induced neuropathy in rodents. Metys Pharma- ceuticals is preparing the first dedicated efficacy study of dimiracetam in this indication.
NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. The company’s lead drug treatment regimen is NRX-100/NRX-101, the first sequential drug treatment regimen for Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB). We have also started to investigate our treatments for PTSD in patients with ASIB.
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe. The company has a broad and growing portfolio, with two compounds in clinical trials, Iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIA in oncology, and Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor for the treatment of multiple sclerosis, Alzheimer’s disease and other neurodegenerative diseases, in Phase IIA, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications. From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of Vafidemstat (ORY-2001) since the start of our CNS research. The company has a seasoned executive management with vast experience in the industry.
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
STALICLA is a mission-driven biotech, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). At STALICLA, we have developed an innovative algorithm platform that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of ASD patients. By identifying these subgroups, we aim to offer repurposed drugs that provide more effective, personalized treatment options. The company was founded in Geneva, Switzerland in May 2017 by today’s CEO Lynn Durham, a biotech entrepreneur with a lifelong involvement with the autism community. STALICLA has established a research partnership with the Greenwood Genetic Center, South Carolina, USA, a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
T3D Therapeutics, Inc. was founded in 2013 to challenge the prevailing thinking over the last two decades in the development of solutions to effectively treat Alzheimer’s disease. Our mission is to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease.
Fundamental to our approach is the recognition that Alzheimer’s disease (refs.1-5) is a neuro-metabolic disease and, as such, we must first address poor energy metabolism and dysfunctional lipid metabolism in the brain – brain ‘starvation’ – which leads to neurodegeneration and brain ‘strangulation’, as evidenced by plaques, tangles and inflammation of the brain (ref. 6).
The brain is the most metabolically active organ in the body and it relies on glucose, or sugar, for fuel (ref. 7). If the brain loses its ability to efficiently process sugar into energy and maintain lipid homeostasis, the brain becomes starved. This ‘starvation’ causes a wasting process that then leads to cognitive and motor function deficits – this is Alzheimer’s disease.
Our lead product candidate, T3D-959, is positioned to become a transformational therapy by targeting both the brain ‘starvation’ and ‘strangulation’ of Alzheimer’s disease and by treating multiple manifestations of the disease.
Tonix is developing innovative pharmaceutical products to address public health challenges, with two therapeutic programs focusing on posttraumatic stress disorder (PTSD). TNX-102 SL or Tonmya® is Tonix's lead product candidate, designed as a bedtime treatment for PTSD, is currently in Phase 3 study in the military-related PTSD population. TNX-601 (tianeptine oxalate), designed as a daytime treatment for PTSD, is in preclinical development. PTSD is a serious condition characterized by chronic disability, inadequate treatment options especially for military-related PTSD and overall high utilization of healthcare services creating significant economic burden. Other products in development include TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.
Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (“IBD”) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. Approximately 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are typically designed to overcome well-known drawbacks of currently available therapies. Vitality’s prodrug technology enables the selective targeting of specific tissues or organs, including the gut or brain, enabling the drug to have a more targeted effect. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.